AIM ImmunoTech Inc. — Director's Dealing 2017

Feb 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-02-16

Reporting Person: STRAYER DAVID R (Chief Science/Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-02-16	Common Stock	P	9892	$0.46	Acquired	33867	Direct